MARCELA RAMIREZ: Open Payments
NPI 1730572306 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,202 in 32 payments from 12 companies in 2025. Trend: 2023 $2,336 · 2024 $1,479 · 2025 $1,202
Food & beverage: $1,117Education: $85
| Company | Payments | Amount |
|---|---|---|
| REVANCE THERAPEUTICS, INC. | 12 | $624 |
| MERZ NORTH AMERICA, INC. | 2 | $111 |
| UCB, Inc. | 2 | $89 |
| SANOFI-AVENTIS U.S. LLC | 1 | $85 |
| Novartis Pharmaceuticals Corporation | 4 | $84 |
| GENZYME CORPORATION | 2 | $63 |
| ABBVIE INC. | 3 | $53 |
| Galderma Laboratories, L.P. | 1 | $35 |
| Incyte Corporation | 1 | $23 |
| LEO Pharma Inc. | 1 | $19 |
Products named: DAXXIFY, DUPIXENT, DAXI, Bimzelx, Xeomin, Rhapsido, RINVOQ, OPZELURA.
Industry payments across TX — which companies pay providers there.
